Month: September 2020

Casino Group announces the initiationof a study from GPA to spin-off Assaí in BrazilParis, 10th September 2020,The Board of Directors of Companhia Brasileira de Distribuição (GPA), subsidiary of Casino Group in Brazil, approved the initiation of a study to segregate its cash and carry unit (Assaí) from the rest of its activities.The goal of this transaction is to unleash the full potential of Assaí, on the one hand, and of the more traditional retail businesses of GPA and Éxito, on the other hand. This operation will allow them to operate on a standalone basis, to focus on their respective business models and market opportunities. They will also benefit from direct access to the capital markets and other sources of funding, creating more value for their respective shareholders.Upon the implementation of the operation, Casino Group, which...

Le Groupe Casino annonce l’ouvertured’une étude de GPA en vue d’un spin-off d’Assaí au BrésilParis, le 10 septembre 2020,Le conseil d’administration de Companhia Brasileira de Distribuição (GPA), filiale du groupe Casino au Brésil, a approuvé le lancement d’une étude en vue de séparer son activité de cash and carry (Assaí) d’avec le reste de ses activités.L’objectif d’une telle opération est d’optimiser le potentiel d’Assaí, d’une part, et des activités de distribution alimentaire plus traditionnelles de GPA et Éxito, d’autre part. Cette opération leur permettra de fonctionner de manière autonome, de se concentrer sur leurs modèles d’entreprise et sur les opportunités de leurs marchés respectifs. Elles bénéficieront par ailleurs d’un accès direct aux marchés de capitaux et aux différentes sources de financement, créant ainsi davantage...

opaganib, 3일간의 인큐베이션 결과 인간 기관지 조직의 in vitro 모델에서 SARS-CoV-2 바이러스 복제 완전히 억제하는 효과가 양성 대조군인 렘데시비르보다 우수—opaganib, 강력한 항바이러스 및 항염증 작용 기제 결합된 경구용 코로나19 치료제 잠재력 갖춰, 숙주 세포 성분을 타깃으로 하며 내성을 최소화—opaganib, 중증 코로나19 폐렴 치료용 글로벌 임상2/3상 및 미국 내 임상2상 연구 진행 중—RedHill의 두 번째 코로나19 치료제 후보인 RHB-107 (upamostat)은 세린단백질가수분해효소 억제제로 동일 모델에서 SARS-CoV-2 바이러스 복제 강력하게 억제하는 신약 후보, 올해 연말로 예정된 미국 내 외래환자 대상 임상2/3상 계획 뒷받침이스라엘 텔아비브/미국 노스캐롤라이나주 롤리, Sept. 10, 2020 (GLOBE NEWSWIRE) — 스페셜티 바이오 제약사인 RedHill Biopharma Ltd. (Nasdaq: RDHL)는 opaganib1이 코로나19 유발 바이러스인 SARS-CoV-2에 대해 강력한 억제 능력을 보여주며 인간 폐 기관지 조직의 in vitro 모델에서 바이러스 복제를 완전하게 차단한다고 밝혔다. opaganib은 스핑고신 키나아제 2(SK2) 저해제인 경구용 혁신 신약으로 숙주 세포 성분을 타깃으로 하는 항염증 및 항바이러스 활동을 동시에 수행하며 바이러스성 돌연변이 영향을 받지 않아 내성을 최소화한다. opaganib은 현재 중증 코로나19 폐렴 치료용으로 글로벌 임상2/3상, 미국 내에서 임상2상 평가가 진행 중이다.자사는 루이빌대 예측의학센터와의 협업을 통해 인간...

TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) — Northfield Capital Corporation (the “Acquiror”) announces that, together with its joint actor (Mr. Robert Cudney), it has acquired ownership and/or control of 1,350,000 common shares (the “Subject Shares”) of Cypress Hills Resource Corp. (the “Company”), #416, 602 – 11th Avenue SW, Calgary, Alberta T2R 1J8, on September 8, 2020 pursuant to share purchase and sale agreements with an existing shareholder of the Company. The Subject Shares represent approximately 6.76% of all issued and outstanding common shares of the Company as of such date. Of this total, 750,000 common shares were acquired by the Acquiror directly, and 600,000 common shares were acquired by its joint actor.Immediately before the transaction described above, the Acquiror held an aggregate of 1,400,000 common shares of the...

HUNTINGTON BEACH, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — BJ’s Restaurants, Inc. (NASDAQ: BJRI) announced today that Chief Executive Officer, Greg Trojan and President and Chief Financial Officer, Greg Levin, will be participating virtually in a fireside chat at CL King’s 18th Annual Best Ideas Conference on September 16, 2020 at 11:45 a.m. (Pacific Daylight Time). BJ’s management will also virtually meet with institutional investors.About BJ’s Restaurants, Inc.BJ’s Restaurants, Inc. (“BJ’s”) is a national brand with brewhouse roots and a menu where craft matters. BJ’s broad menu with a wide variety of menu offerings has something for everyone: slow-roasted entrees, like prime rib, BJ’s EnLIGHTened Entrees® including Cherry Chipotle Glazed Salmon, signature deep dish pizza and the often imitated, but never replicated...

CALGARY, Alberta, Sept. 09, 2020 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado” or the “Company”) (TGH: TSX-V) today reported the voting results from its Annual and Special Meeting of Shareholders held on September 9, 2020 (the “Meeting”).All of the six nominees proposed by management for election to the Board of Directors at the Meeting and listed in the Company’s Management Information Circular dated August 3, 2020 were elected. The directors elected at the Meeting will hold office until the next annual meeting of shareholders, or until their successors are elected or appointed.The results of the vote on the election of the Board of Directors are as follows:Additionally, resolutions were passed at the Meeting approving: (i) the appointment of MNL LLP as auditors of the Company, passed with 99.99% of votes cast in...

TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A, DC.PR.B and DC.PR.D) (“Dundee” or the “Corporation”) announced today the results of its substantial issuer bid, as amended (the “Offer”), to purchase for cancellation from the holders thereof all of its issued and outstanding Cumulative 5-Year Rate Reset First Preference Shares, Series 2 in the capital of the Corporation (the “Series 2 Shares”) at a fixed price of C$19.50 per Series 2 Share. The Offer expired at 5:00 p.m. (Toronto time) on September 8, 2020.Based on the report of Computershare Investor Services Inc., as depositary for the Offer (the “Depositary”), approximately 1,966,816 Series 2 Shares were tendered to the Offer. In accordance with the terms and conditions of the Offer and based on the Depositary’s report, the Corporation has taken up and...

FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 11:00 a.m. ET.A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.About VaxcyteVaxcyte is a next-generation vaccine company seeking to improve global health by developing superior...

Simon Burton – Chief Executive Officer and Chief Underwriting OfficerNeil Greenspan – Chief Financial OfficerFaramarz Romer – Chief Accounting Officer and TreasurerGRAND CAYMAN, Cayman Islands, Sept. 09, 2020 (GLOBE NEWSWIRE) — Greenlight Capital Re, Ltd. (Nasdaq: GLRE) (“Greenlight Re” or the “Company”), a specialist property and casualty reinsurance company headquartered in the Cayman Islands, today announced that its Board of Directors (the “Board”) has appointed Greenlight Re’s Chief Executive Officer, Simon Burton, to serve also as the Company’s Chief Underwriting Officer, Neil Greenspan to serve as Chief Financial Officer, and Faramarz Romer to serve as Chief Accounting Officer and Treasurer, each effective immediately. The Company also announced the resignations of Brendan Barry and Tim Courtis as of September 4, 2020...

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has completed a Type C ‘written response only’ meeting with the Office of Tissues and Advanced Therapies (OTAT), part of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), to obtain OTAT’s concurrence on the commencement of its next clinical trial for SRP-9001 using commercial process material. SRP-9001 (AAVrh74.MHCK7.micro-dystrophin) is Sarepta’s investigational gene transfer therapy for the treatment of Duchenne muscular dystrophy.Among other items, OTAT has requested that Sarepta utilize an additional potency assay for release of SRP-9001 commercial process material prior to dosing in a clinical study....